The WHI selected at random post-menopausal women to receive CEE 0.625mg/day plus medroxyprogesterone acetate 2.5mg/day, known as the estrogen/progestin arm of the study. 
of women most likely to use it (ages 50-60), there is an unquestioned desire to provide safer alternatives to treat menopausal symptoms.
Even now, estrogen remains the only therapy approved by the US Food and Drug Administration (FDA) for the treatment of vasomotor symptoms. In multiple randomized trials, HT reduced the frequency and severity of hot flushes by 60% to 95%, with generally similar efficacy regardless of type of preparation or route of administration. 5 Since HT is still regarded as the most effective therapy, the challenge has been to develop safer strategies for HT for the large numbers of women seeking relief from these symptoms. This 
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Hormone Therapy
The WHI selected at random post-menopausal women to receive CEE 0.625mg/day plus medroxyprogesterone acetate 2.5mg/day, known as the estrogen/progestin arm of the study. CEE alone was administered if the woman had undergone hysterectomy with corresponding placebo groups, which formed the estrogen-only arm of the study. On a practical note, despite enhanced relative risk for adverse events in the WHI, the absolute risk with use of estrogen or combined HT was low, with an increase of eight breast cancer cases and seven cases of cardiovascular disease per 10,000 person-years in the combined HRT arm. 1 In contrast, the recent combined analysis showed six fewer cardiovascular events per 10,000 treated women if the women were less than 10 years from menopause. 4 The true effect of menopausal hormones on development of breast cancer is also difficult to discern. The combined HT arm of the WHI had eight more breast cancer cases per 10,000 treated women, whereas the estrogen-only arm showed approximately eight fewer breast cancers per 10,000 women. 1, 2 The publicity following the 2002 publication of the combined treatment findings led to a 50% decrease in the use of HT in the US. 7, 8 Coincident with the decline in estrogen use, a recent epidemiological study noted that the incidence of breast cancer in the US decreased 6.7% in 2003. 9 However, a potential confounder in this observational study was that mammograms were performed in 3.2% Other recent carefully done hot flush studies show SSRI treatment to be no different from a placebo response. 13 Selective estrogen-receptor modulators (SERMs) are synthetic compounds that bind estrogen receptors and produce tissue-dependent agonistic or antagonistic activity. A three-year randomized trial for treatment of osteoporosis in post-menopausal women showed a worsening of vasomotor symptoms with raloxifene.
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Efficacy of Low-dose Estrogen for Menopausal Symptoms
In its most recent position statement, the North American Menopause Society concluded that current evidence supports the use of estrogen therapy or estrogen-progestogen therapy for menopause-related symptoms and disease prevention in appropriate populations of peri-and post-menopausal women. 15 To reduce estrogen-related adverse effects and limit long-term serious risk of estrogen treatment, various expert groups have advocated use of the lowest effective dose of estrogen or combined hormonal therapy for the shortest duration. [15] [16] [17] Furthermore, the FDA now requires manufacturers to identify the lowest effective dose for new products. other estrogen that has shown efficacy at a similarly ultra-low dose that is approved for preventing bone loss in post-menopausal women, but is not approved to treat vasomotor symptoms, is a 0.014mg/d transdermal estradiol patch (Menostar ® , Berlex Laboratories). 22 The clinical relevance of these findings is that more than one large controlled study has demonstrated efficacy of these ultra-low estradiol doses in treating various menopausal symptoms.
Safety and Tolerability of Low-dose Estrogen
As it avoids first-pass hepatic metabolism, transdermal delivery permits use of lower doses of estradiol and induces a less pronounced effect on hepatic protein synthesis. 23 In general, markers of coagulation and fibrinolysis remain relatively unchanged after transdermal estrogen, whereas oral estrogen has more pronounced influences on hemostatic variables including hyper-coagulant effects, increased synthesis of C-reactive protein, and increased fibrinolytic markers. 24, 25 Both oral and transdermal estrogen lead to potentially antiatherogenic changes in lipoproteins, such as lowering lowdensity lipoprotein cholesterol (LDL-C) and increasing high-density lipoprotein cholesterol (HDL-C), although the transdermal route has less impact on HDL-C. 26 New epidemiological evidence identifies differences in the risk of venous thromboembolism (VTE) between oral and transdermal HT and as a function of the estrogen dose. Evidence for a differential association of oral and transdermal estrogen with the risk for VTE was first obtained from the ESTHER trial, a French case-controlled study that noted a 3.5-to 4.0-fold higher risk of VTE for users of oral HT but no increased risk with transdermal HT. 27, 28 Another study showed that in women carrying either a factor V Leiden mutation or a prothrombin G mutation, the use of oral estrogen but not transdermal estrogen significantly increased the already heightened risk of VTE conferred by these mutations. 29 Case-control studies have also demonstrated a dosedependent risk for VTE, with low-dose CEE associated with lower risk 30 or no risk. 31 Whether the lower risk for VTE demonstrated with the transdermal route or with reduced doses of estrogen can be extrapolated to atherosclerotic cardiovascular disease remains to be determined.
As the frequency of side effects with estrogen therapy are dose-related, It remains unclear whether the breast cancer risk can be modulated with low-or ultra-low-dose estrogen or transdermal delivery. A dose effect of estrogen on breast cancer risk appears possible because elevated endogenous estrogen levels are associated with a higher breast cancer risk. 33 A recent large epidemiological study showed an enhanced risk of breast cancer after five years of use of either oral or transdermal estradiol therapy; a trend toward dose-responsiveness was noted only with oral dosing. 34 In addition, since both observational and prospective studies show an elevated risk with progestin-containing regimens of HT, 1,2,35 a concomitant reduction in exposure to progestin with low-or ultra-low-dose estrogen may (if shown in large controlled studies) potentially lead to a lower breast cancer risk.
Reducing Exposure to Progestin
Progestin is added to estrogen therapy to counter the proliferative effects of estrogen on the endometrium and decrease endometrial hyperplasia and endometrial cancer. 36 As noted, the WHI documented an adverse progestin effect. Although the two arms were not compared directly, only the combined HT group showed a significantly enhanced risk for cardiovascular events, (HR Post-menopausal Hormone Therapy-Improving the Risk-Benefit Ratio with Ultra-low Doses of Estrogen
Since the risk of endometrial hyperplasia with unopposed estrogen is doseand duration-related, less progestin may prove necessary to provide endometrial protection when using the lowest doses of estrogens for HT. 37 A lower exposure to progestin could be attained with reduced frequency of use. The combination of low-dose estrogen (CEE 0.3mg) and long-cycle progestin (every six months) was shown to reduce menopausal symptoms and vaginal bleeding without increasing uterine hyperplasia. 38 With ultralow doses of estrogen, progestin doses may be reduced even further, with the need for progestin coverage conceivably eliminated in some cases. In the osteoporosis study noted above, the 0.014mg/d transdermal estradiol patch showed minimal endometrial stimulation after two years of use, with only one case of endometrial hyperplasia (0.5%). 39 These data suggest that women using similar ultra-low doses of transdermal estrogen may not require progestin treatment, but due to the lack of long-term clinical data on the safety of unopposed ultra-low estrogen dosing, current labeling for
Menostar stipulates use of a progestin for 14 days every six to 12 months and an annual endometrial biopsy.
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Conclusions
The need for safe, effective treatment of menopausal symptoms persists for symptomatic relief of menopausal symptoms, these ultra-low doses of estrogen should be considered. ■
